Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Safety of SHR-1819 Injection Devices in Healthy Subjects
NCT07264335Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SHR-1819 in atopic dermatitis (AD) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Area under the serum concentration versus time curve from time zero to the real time of last measurable concentration and Peak concentration. Started Mar 2026; status: completed.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07264335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264335.